Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Intrathecal baclofen for severe spasticity.

G J Hankey, E G Stewart-Wynne, D Perlman

    The Medical Journal of Australia
    |November 3, 1986
    PubMed
    Summary

    Intrathecal baclofen, delivered via an implanted system, offers a new treatment for severe multiple sclerosis spasticity unresponsive to oral medications. This approach complements physical therapy for managing debilitating muscle stiffness.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Economic evaluation of the Very Early Rehabilitation in SpEech (VERSE) intervention.

    Topics in stroke rehabilitation·2023
    Same author

    Hearing Impairment and Incident Frailty in Later Life: The Health in Men Study (HIMS).

    The journal of nutrition, health & aging·2023
    Same author

    Beyond Stroke Prevention in Atrial Fibrillation: Exploring Further Unmet Needs with Rivaroxaban.

    Thrombosis and haemostasis·2018
    Same author

    Risk of prevalent and incident dementia associated with insulin-like growth factor and insulin-like growth factor-binding protein 3.

    Molecular psychiatry·2017
    Same author

    Depression as a modifiable factor to decrease the risk of dementia.

    Translational psychiatry·2017
    Same author

    Cerebral small vessel disease, medial temporal lobe atrophy and cognitive status in patients with ischaemic stroke and transient ischaemic attack.

    European journal of neurology·2016

    Area of Science:

    • Neurology
    • Pharmacology

    Background:

    • Severe spastic paraparesis in multiple sclerosis often presents challenges in management.
    • Oral antispasticity agents may be ineffective for some patients.
    • Physical therapy is a cornerstone but may require adjunct treatments.

    Observation:

    • A case study details the use of an implanted subcutaneous drug delivery system for intrathecal baclofen administration.
    • The patient presented with severe spastic paraparesis secondary to multiple sclerosis.
    • This method bypasses the blood-brain barrier for direct spinal cord drug delivery.

    Findings:

    • Intrathecal baclofen effectively managed severe spasticity in a patient with MS.
    • The implanted system provided a continuous and controlled delivery of baclofen.
    • This therapeutic strategy was effective for spasticity unresponsive to oral treatments.

    Implications:

    • Intrathecal baclofen represents a significant therapeutic option for refractory MS spasticity.
    • This approach can be an adjunct to physical therapy, enhancing functional outcomes.
    • Implanted drug delivery systems show promise for managing complex neurological conditions.

    Related Experiment Videos